© 2019 by ArrayGenomics ltd

  • LinkedIn - Grey Circle
  • White Twitter Icon

What ArrayGenomics can offer to patients with bladder cancer.

ArrayGenomics has developed innovative, non-invasive, molecular diagnostic tests for urological cancers (bladder, prostate and kidney) with higher sensitivity than traditional tests.


This enables patients to receive the most appropriate treatment.

Simply put our test offers the most accurate results just by analysing a patient's urine sample.
Nothing could be easier or more painless. 

ArrayGenomics is leading the revolution in bladder cancer surveillance. 

One of the most common symptoms of bladder cancer is the presence of blood in urine. This discovery can lead to a stressful time for patients who need to be guided and treated as soon and as well as possible.
 

The BCA test from ArrayGenomics is designed to help doctors and medical professionals make the right choice of treatment for their patients. 

The BCA test is non-invasive and yet it is still able to provide the most accurate results of all existing techniques. 

 

No pain, no surgery, less stress, less time in hospital, more time spent at home.

 

Cytoscopy is the preferred choice when bladder cancer is suspected. In a recent study comparing BCA to cystoscopy (available here) it was found that half of the cystoscopies were performed unnecessarily. 49 patients (51%) of the 95 who showed a negative cystoscopy were also found to be negative with BCA. If BCA had been used alone, these patients would not have been identified as needing a cystoscopy, thereby saving money and contributing to patient welfare. 

In the same study we demonstrated that the BCA test was able to detect bladder cancer earlier than cystoscopy.

ArrayGenomics is leading the revolution in bladder cancer surveillance. 

How does the test work? 

BCA vs Cystoscopy 

In the opinion of both the American and European Associations of Urology, a cystoscopy:

 

  1. Is an invasive, painful and costly clinical procedure
     

  2. Should be carried out 2 - 4 times p.a. for at least 5 years or more after initial diagnosis, Often this is for life, for example for routine checks
     

  3. Is unpleasant for the patient, it has been shown that over 40% of patients opt out*
     

  4. Can lead to pain after the examination is performed 
     

  5. Can lead to:

    •                   Urinary tract infections

    •                   Patients unable to empty their bladder

    •                   Bleeding and bladder damage

    •                   Infections

    •                   Error in diagnosis


 

Clinicians have long been searching for a urine-based, non-invasive test that equals or exceeds the sensitivity of cystoscopy (70-90%) so as to avoid unnecessary cystoscopies.

BCA is a non-invasive test that has sensitivity levels that exceed 90% with a lower cost solution than cystoscopy.

Other current commercial tests miss close to 1 out of 3 bladder cancers

 

 


 

* . Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J. Natl Cancer Inst. 2003;95:588–597. [available here]